About the Study The goal of this study is to examine the effectiveness of lactoferrin, an over-the-counter dietary supplement isolated from bovine milk whey, in treating early COVID-19. Currently, there are few treatment options available for those with COVID-19; lactoferrin potentially represents a commercially available treatment option to those with COVID-19 who are not sick [...]
The U-M Center for Drug Repurposing has built a drug repurposing platform to address Covid19. We have developed several human cell-based SARS-CoV-2 infection models and have screened FDA approved drugs, clinical candidates and some dietary supplements. Morphological profiling of SARS-CoV-2 infected Huh7 cells (MOI of 0.2 for 48 hrs). A) Clockwise: Representative field with [...]
Researchers at the Broad Institute, Dana Farber Cancer Institute, MIT and Harvard just published a drug repurposing screen in Nature Cancer of 4,518 compounds, mostly FDA approved drugs and clinical candidates against 578 human cancer cell lines. The technology that enabled this massively parallel anticancer drug discovery approach is the PRISM bar-coded cell lines [...]
The National Center for Advancing Translational Sciences (NCATS) has developed Inxight: Drugs A comprehensive portal for drug development information. NCATS Inxight: Drugs contains information on ingredients in medicinal products, including: US APPROVED DRUGS: 2,553 MARKETED DRUGS: 6,161 INVESTIGATIONAL DRUGS: 6,791 ALL SUBSTANCES: 102,012 2018 Overview of FDA Approved Drugs: - Highest ever number of innovative drugs approved in a year. - FDA approves first-ever RNAi therapeutic. [...]
A meta-analysis of 17 trials for seven drugs (acetazolamide, donepezil, mirtazapine, ondansetron, paroxetine, protriptyline, theophylline) indicated a small effect for acetazolamide (mean difference in AHI -9.6/h [-17.7; -1.4]; p = 0.02). In the network meta-analysis (I2 = 50%) nine drugs (tramazoline, liraglutide, spironolactone/furosemide, acetazolamide, dronabinol, zonisamide, phentermine, spironolactone, and ondansetron/fluoxetine) significantly lowered the AHI compared to placebo.
Repositioning Drugs to Improve Metabolic Control in Established Type 1 Diabetes: The JDRF has announced a new grant opportunity for drug repurposing or drug repositioning to improve metabolic control in type-I diabetes. The majority of type-I and type-II diabetics fail to achieve an HbA1c goal of <7%. This grant seeks to fund investigators to [...]
